BACKGROUND: Endothelial cell (EC) dysfunction contributes to hypertension and mechanisms of atherosclerosis. Agents that improve EC function may provide vascular protection, especially in patients with multiple risk factors. In this study, we examined the effects of beta(1)-selective antagonists, nebivolol and metoprolol, on vascular and renal EC function in spontaneously hypertensive (SH) rats with diabetes. METHODS: Male SH rats were treated with streptozotocin (STZ) to induce type 2 diabetes, followed by treatment with nebivolol or metoprolol at 2 mg/kg/day (vs. vehicle). After 4 weeks, aortic and glomerular ECs were isolated, stimulated with calcium ionophore (CaI), and assayed for nitric oxide (NO), and peroxynitrite (ONOO(-)) release using amperometric approaches. RESULTS: Glucose and mean blood pressure (BP) levels were significantly elevated in diabetic SH rats. In aortic ECs isolated from diabetic SH rats, NO production decreased by 20% whereas ONOO(-) increased by 16%, an effect linked to NAD(P)H oxidase and endothelial NO synthase (eNOS) uncoupling. Nebivolol treatment reduced glucose and BP levels and restored aortic EC function in diabetic SH rats, as indicated by a 30% increase and 23% decrease in NO and ONOO(-) levels, respectively. The NO/ONOO(-) ratio increased by more than twofold with nebivolol treatment in aortic and glomerular ECs. Despite similar reductions in glucose and mean BP levels, metoprolol had a smaller effect on the NO/ONOO(-) ratio in glomerular ECs but no effect in aortic ECs. CONCLUSIONS: Vascular and renal NO was significantly reduced in diabetic hypertensive rats and correlated with metabolic changes. Nebivolol reversed these effects in a manner consistent with enhanced endothelial function.
BACKGROUND: Endothelial cell (EC) dysfunction contributes to hypertension and mechanisms of atherosclerosis. Agents that improve EC function may provide vascular protection, especially in patients with multiple risk factors. In this study, we examined the effects of beta(1)-selective antagonists, nebivolol and metoprolol, on vascular and renal EC function in spontaneously hypertensive (SH) rats with diabetes. METHODS: Male SH rats were treated with streptozotocin (STZ) to induce type 2 diabetes, followed by treatment with nebivolol or metoprolol at 2 mg/kg/day (vs. vehicle). After 4 weeks, aortic and glomerular ECs were isolated, stimulated with calcium ionophore (CaI), and assayed for nitric oxide (NO), and peroxynitrite (ONOO(-)) release using amperometric approaches. RESULTS:Glucose and mean blood pressure (BP) levels were significantly elevated in diabetic SH rats. In aortic ECs isolated from diabetic SH rats, NO production decreased by 20% whereas ONOO(-) increased by 16%, an effect linked to NAD(P)H oxidase and endothelial NO synthase (eNOS) uncoupling. Nebivolol treatment reduced glucose and BP levels and restored aortic EC function in diabetic SH rats, as indicated by a 30% increase and 23% decrease in NO and ONOO(-) levels, respectively. The NO/ONOO(-) ratio increased by more than twofold with nebivolol treatment in aortic and glomerular ECs. Despite similar reductions in glucose and mean BP levels, metoprolol had a smaller effect on the NO/ONOO(-) ratio in glomerular ECs but no effect in aortic ECs. CONCLUSIONS: Vascular and renal NO was significantly reduced in diabetic hypertensiverats and correlated with metabolic changes. Nebivolol reversed these effects in a manner consistent with enhanced endothelial function.
Authors: Andrew S Cowburn; Norihiko Takeda; Adam T Boutin; Jung-Whan Kim; Jane C Sterling; Manando Nakasaki; Mark Southwood; Ananda W Goldrath; Colin Jamora; Victor Nizet; Edwin R Chilvers; Randall S Johnson Journal: Proc Natl Acad Sci U S A Date: 2013-10-07 Impact factor: 11.205
Authors: Camila Manrique; Guido Lastra; Javad Habibi; Lakshmi Pulakat; Rebecca Schneider; William Durante; Roger Tilmon; Jenna Rehmer; Melvin R Hayden; Carlos M Ferrario; Adam Whaley-Connell; James R Sowers Journal: Metabolism Date: 2011-06-02 Impact factor: 8.694
Authors: Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen Journal: Br J Clin Pharmacol Date: 2015-06-05 Impact factor: 4.335
Authors: R Preston Mason; Robert F Jacob; J Jose Corbalan; Roman Kaliszan; Tadeusz Malinski Journal: Am J Hypertens Date: 2013-10-29 Impact factor: 2.689
Authors: R Preston Mason; Robert F Jacob; J Jose Corbalan; Damian Szczesny; Kinga Matysiak; Tadeusz Malinski Journal: BMC Pharmacol Toxicol Date: 2013-09-28 Impact factor: 2.483
Authors: Regina Pawlak-Chomicka; Tomasz Krauze; Pawel Uruski; Jaroslaw Piskorski; Andrzej Wykretowicz; Andrzej Tykarski; Przemyslaw Guzik Journal: Cardiol Res Pract Date: 2022-03-31 Impact factor: 1.866